Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JJH201601 liposome in advanced pancreatic cancer, biliary tract cancer, and hepatocellular carcinoma
CTR20243699Phase 2Active
- Sponsor
- Jiangsu Jibeier Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JJH201601 liposome in pancreatic cancer (PC), biliary cancer and hepatocellular carcinoma (HCC), sponsored by Jiangsu Jibeier Pharmaceutical. Primary endpoint: Objective response rate. Started Oct 2024; status: active.
02
Drugs
JJH201601 liposome
03
Conditions
pancreatic cancer (PC)biliary cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20243699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243699.